Laetitia Devy-Dimanche | CEO
ACLRT.Bio

Appearances:

The Lifecycle Paradox & Value Destruction Billions of R&D capital are lost annually due to poor execution and fragmented early-development capabilities. In the traditional biotech lifecycle, value is systematically destroyed when teams are disbanded after an exit or asset failure, forcing the next innovation to start from zero and waste years recreating institutional knowledge.
The Talent Trap in Biologics With only 20% of assets successfully moving from pre-IND to Proof-of-Concept (PoC), the operational risk of building a high-performing team from scratch is often higher than the scientific risk. Assembling a senior, multi-disciplinary team for CMC, regulatory, and clinical operations takes years—time that most early-stage assets simply do not have.
A New Model: Biotech-as-a-Service (BaS) The industry must shift from a "hire-and-build" approach to a plug-and-play development engine. By embedding an exit-proven leadership team—acting as operating partners rather than transactional vendors—portfolios can bridge assets from IND to PoC faster, maximizing the "dollars-into-the-clinic" ratio while providing a layer of operational risk management between capital and the clinic.